Publications by authors named "A Vezzelli"
Development and validation of a bioanalytical method for the quantification of CHF6550 and its metabolite (CHF6671) in rat plasma and lung homogenate using LC-MS/MS.
J Chromatogr B Analyt Technol Biomed Life Sci
May 2023
A selective and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for accurate determination of CHF6550 and its main metabolite in rat plasma and lung homogenate samples. All biological samples were prepared by simple protein precipitation method using deuterated internal standards. The analytes were separated on a HSS T3 analytical column with 3.
View Article and Find Full Text PDFIOA-289 is a novel small molecule inhibitor of autotaxin developed as a first-in-class therapy of fibrotic pathologies including cancer. A method for quantitation of IOA-289 in human plasma was developed using a stable isotope labeled compound ([C]IOA-289) as internal standard. The analytes were extracted from human plasma by protein precipitation and the analysis was performed by liquid chromatography coupled with tandem mass spectrometric detection (LCMS/MS).
View Article and Find Full Text PDFPharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing .
Antimicrob Agents Chemother
May 2020
Article Synopsis
- * A study investigated the effectiveness of cefepime combined with the beta lactamase inhibitor enmetazobactam against ESBL-producing bacteria using a mouse model for pneumonia, focusing on how the drugs distribute and act in the lungs.
- * Results showed that while cefepime alone was minimally effective, combining it with enmetazobactam significantly enhanced its antimicrobial action, indicating a promising new treatment strategy for serious infections caused by ESBL-producing organisms.
Article Synopsis
- A method using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was created to analyze enmetazobactam and cefepime in human plasma samples.
- *The process involved protein precipitation with acetonitrile and separation through a specific HILIC column using a mobile phase made from ammonium formate in water and acetonitrile.
- *Validation results showed high precision and accuracy, with a lower limit of quantification of 0.05 μg/mL for enmetazobactam and 0.5 μg/mL for cefepime across multiple tests.
LNA-i-miR-221, a 13-mer oligonucleotide, is a new miR-221 inhibitor that could be used as a novel drug for multiple myeloma. Herein, an ion-pair reversed phase liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the quantification of LNA-i-miR-221 in rat plasma. Plasma samples were prepared with an initial phenol/chloroform/isoamyl alcohol liquid-liquid extraction followed by a solid phase extraction.
View Article and Find Full Text PDF